NCT06678659 A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
| NCT ID | NCT06678659 |
| Status | Recruiting |
| Phase | Phase 1, Phase 2 |
| Sponsor | Recursion Pharmaceuticals Inc. |
| Condition | Unresectable |
| Study Type | INTERVENTIONAL |
| Enrollment | 170 participants |
| Start Date | 2024-11-21 |
| Primary Completion | 2028-10-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 170 participants in total. It began in 2024-11-21 with a primary completion date of 2028-10-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Eligibility Criteria
Inclusion Criteria: * Have histologically-confirmed unresectable, locally advanced, or metastatic select solid tumors or select relapsed / refractory lymphoma * Have experienced progressive disease, relapsed disease, or be intolerant to at least one established standard systemic anti-cancer treatment for a given tumor type, or have been considered ineligible for standard therapy. * Eastern cooperative oncology group (ECOG) performance status ≤1; for adolescent participants, Lansky Performance Status Scale or Karnofsky Performance Status Scale score of ≥70. * Measurable disease at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 / Lugano criteria and documented by computed tomography (CT) and / or magnetic resonance imaging (MRI) Exclusion Criteria: * Received treatment with another RBM39 degrader * Clinically significant gastrointestinal (GI) or GI malabsorption
Frequently Asked Questions
Who can join the NCT06678659 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Unresectable. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06678659 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06678659 currently recruiting?
Yes, NCT06678659 is actively recruiting participants. Visit ClinicalTrials.gov or contact Recursion Pharmaceuticals Inc. to inquire about joining.
Where is the NCT06678659 trial being conducted?
This trial is being conducted at Duarte, United States, Cleveland, United States, Nashville, United States, West Valley City, United States and 2 additional locations.
Who is sponsoring the NCT06678659 clinical trial?
NCT06678659 is sponsored by Recursion Pharmaceuticals Inc.. The trial plans to enroll 170 participants.